ALISO VIEJO, Calif., Nov. 26, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced the launch of its VisiLoc(tm) MRI visible obturator (http://www.senorx.com/visiloc.pdf), compatible with its EnCor(r) breast biopsy system, at the annual meeting of the Radiological Society of North America (RSNA) in Chicago. The product facilitates location of a lesion for breast biopsy under MRI image guidance.
SenoRx President and Chief Executive Officer Lloyd Malchow said, "VisiLoc gives us the opportunity for a competitive advantage in the rapidly growing MRI breast biopsy market and enhances our ability to compete for placement of our EnCor breast biopsy system. Together with the recent introduction of our SenoSonix(tm) system, an integration of the EnCor breast biopsy system with state-of-the-art ultrasound imaging from Ultrasonix Medical, and the introduction of our new EnCor Fire Forward for stereotactic imaging, we have further strengthened our EnCor Breast Biopsy product platform."
Commenting on his experience with VisiLoc, Dr. Daniel J. White, President of MRI Advance of Columbus, Ohio, said, "Using the VisiLoc, I find that it is very easy to locate the targeted biopsy area, whether looking at the image in the sagittal or axial plane. To find something black in the midst of something black is very difficult. But with the VisiLoc, the obturator was plainly visible, providing verification of the targeted geographic area. The VisiLoc may provide physicians with a valuable new device to help deliver high-quality care to patients."
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its flagship EnCor(r) system and Contura(tm) MLB. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 18 products having received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
About EnCor(r)
SenoRx's flagship diagnostic product, the EnCor(r) system, is a minimally invasive, vacuum-assisted breast biopsy system. EnCor allows users to obtain multiple biopsy samples with a quick, single probe insertion. EnCor is the only "open/closed" tissue collection system, providing the operator with a clear view of tissue samples through a proprietary transparent collection chamber, and the ability to either open the chamber to examine and remove one or more samples or to continue uninterrupted collection of multiple samples. EnCor incorporates novel programmability, which allows the user to select automated cutting patterns, tissue density and number of samples, and to deliver anesthetic. EnCor is compatible with all three imaging modalities -- Ultrasound, Stereotactic and MRI -- and because of its modular design, easy software upgrades keep the operating system current. EnCor received 510(k) clearance from the U.S. Food and Drug Administration in late 2004, and began full commercial launch in November 2005.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the possibility that VisiLoc will enhance the company's competitive position, SenoRx's future growth and VisiLoc's market adoption are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its prospectus dated March 29, 2007 and its most recent quarterly report on Form 10-Q, in each case as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.